Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
This research evaluates strategies to improve follow-up care after hospital stays for children with bronchiolitis, an acute lung condition. It focuses on comparing two different multi-component approaches intended to increase as-needed PRN follow-up prescriptions by hospital doctors and reduce unnecessary routine follow-up visits by families. The study is led by Seattle Childrens Hospital and addresses a common practice that may often result in unnecessary visits. Participants are divided into three groups those experiencing a moderate-resource implementation strategy, a high-resource implementation strategy, or no intervention as concurrent controls. The moderate-resource strategy involves educational outreach with family materials, audit and feedback on clinician performance, and clinical decision support tools. The high-resource strategy adds small-group facilitation and expert coach-led support on top of the moderate components. Concurrent control hospitals do not receive any intervention but still collect data. During the study, researchers will track adoption of PRN follow-up prescribing within 7 days after hospital discharge and monitor sustainment of these practices. Families and clinicians will be involved in decision-making supported by educational materials. The study will observe how these strategies affect follow-up visit attendance and clinical practice over time, aiming to optimize care for children hospitalized with bronchiolitis. The study runs from November 2025 to December 2029 for children aged up to 24 months.
Actively Recruiting
Researchers are evaluating the new medicine PF-08634404 in combination with chemotherapy compared to the current standard treatment pembrolizumab with chemotherapy for adults with locally advanced or metastatic non-small cell lung cancer NSCLC. The study includes adults with Stage IIIBIIIC or Stage IV squamous or non-squamous NSCLC who are not candidates for surgery or curative chemoradiotherapy and have not received prior treatment for advanced disease. Participants are assigned to two parts based on tumor type squamous NSCLC Part 1 or non-squamous NSCLC Part 2. Each participant is randomly assigned to receive either PF-08634404 or pembrolizumab with chemotherapy followed by maintenance therapy. Treatment is given through intravenous infusions in cycles, continuing as long as it is effective and safe. Different chemotherapy regimens are used depending on the tumor type. Throughout the study, participants attend regular visits for treatment and health monitoring. Cancer response is assessed every 6 weeks for the first 48 weeks and then every 12 weeks. Researchers will measure overall survival, progression-free survival, objective response rates, duration of response, adverse events, laboratory results, drug levels, immune response, and quality of life using questionnaires. The study lasts up to approximately 39 months with ongoing safety and effectiveness evaluations.